Gilead Sciences (France)

Gilead Sciences (France)

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Gilead Sciences (France), France, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

52%


Total
Publications

167


Total Open
Publications

87


Total
Citations

3.9K


Open Access
Percentage

52%


Total
Publications

167


Total Open
Publications

87


Total
Citations

3.9K

Wikipedia

Website

download

Breakdown

36% 11% 5% 48%

Publisher Open

36%

Both

11%

Other Platform Open

5%

Closed

48%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0246810121416182022Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

24%OA Journal

OA Journal 24%

19

Hybrid 26%

20

No Guarantees 50%

39

Other Platform Open

Domain 81%

22

Preprint 11%

3

Other Internet 11%

3

Institution 7%

2

Public 4%

1

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
22
Europe PMC
Domain
13
Unknown Repository
Other Internet
2
University of Southern Denmark - University of Southern Denmark Research Portal
Institution
2
University of Bristol - Bristol Research
Institution
2
Research Square
Preprint
2
DOI
Other Internet
2
University of Zurich - Zurich Open Repository and Archive
Institution
1
Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB
Institution
1
Semantic Scholar
Public
1
1 / 2

Data updated 13 May 2024

Share

Share

Share